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Abstract The human serotonin 5-HT2B receptor, isolated from a human liver cDNA library, was transfected in COS-I cells. Its pharmacological 
profile shows divergence with serotonin 5-HT2B receptors of other species. In particular, although strong correlation is observed between the human 
and the rat 5-HT2B receptor pharmacology, the correlation is almost as significant for the mouse 5-HT2B and the human 5-HT1D receptor agonists. 
The major sites of expression of its mRNA are in the human liver and kidney, with detectable expression in lung and heart. Therefore, this human 
5-HT2B receptor could account for functions attributed to he peripheral 5-HTI D/5-HT2-1ike r ceptors, especially in the cardiovascular system. Thus, 
its detailed original pharmacology is of prime importance for therapeutic drug development. 
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1. Introduction 
The large diversity of functions of the monoamine serotonin 
(5-hydroxytryptamine, 5-HT) [1] is paralleled by the pharma- 
cological complexity of serotonin receptors. At least four 
classes have been distinguished pharmacologically: 5-HT1, 
5-HT2, 5-HT3, and 5-HT4. These categories are defined by bind- 
ing and effector coupling properties of the receptors [2,3]. Mo- 
lecular biological data have confirmed the existence of multiple 
serotonin receptors, including both ligand-gated receptors 
(5-HT3) and G protein-coupled receptors (GPRs) [4]. This later 
class can be split into three classes [5,6], reflecting the second 
messenger system to which the receptor is coupled: the 5-HT2 
subfamily which is coupled to the activation of the phospholip- 
ase C, the 5-HTI family which interacts negatively with the 
adenylyl cyclase, and the family including 5-HT4, 5-HT6 and 
5-HT7 receptor subtypes which interacts positively with the 
adenylyl cyclase. 
5-HT2 receptors mediate many of the central nd peripheral 
physiological functions of serotonin. Cardiovascular effects in- 
clude contraction of blood vessels and shape change in plate- 
lets; central nervous system effects include neuronal sensitisa- 
tion to tactile stimuli and mediation of hallucinogenic effects 
of lysergic acid diethylamide and related phenylisopropylamine 
hallucinogens. Many investigators have observed that 5-HT2A 
and 5-HT2C receptors do not reflect all the properties attri- 
buted to them. For example, some 5-HT2-1ike effects of sero- 
tonin on peripheral smooth muscles are classified as 'atypical', 
leading to the hypothesis that other 5-HT2 receptor subtypes 
might exist and differ in different species [7]. We reported pre- 
viously the cloning of a new 5-HT2 receptor, the mouse 
5-HT2B receptor [8]. A similar receptor but with distinct ex- 
pression and pharmacology has been described in the rat fun- 
dus [9,10]. 
We report here the detailed pharmacological and molecular 
characterisation of the human 5-HT2B receptor and show that, 
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pharmacologically, it is distantly related to the rat and mouse 
5-HT2B receptors, and that its tissue distribution is species 
specific. Therefore, this new human 5-HT2B receptor may ac- 
count for atypical peripheral 5-HT 1 D/5-HT2-1ike receptor sub- 
types. 
2. Materials and methods 
2.1. Drugs and chemicals 
Restriction endonucleases, AMV reverse transcriptase, DNA poly-
merase I, T4 polynucleotide kinase, T4 DNA ligase, T3 or T7 RNA 
polymerase, were purchased from Bethesda Research Laboratories, 
New England Biolabs, Boerhinger-Mannheim, and Stratagene. Taq 
polymerase for PCR was purchased from Perkin Elmer-Cetus. Ket- 
anserin, ritanserin and setoperone were kindly provided by Janssen 
(Beerse, Belgium). ICS 205-930, LY 53857 and MDL 72 222 were gifts 
from Sandoz (Basel, Switzerland), Lilly (Indianapolis, USA) and 
Merell-Dow (Strasbourg, France), respectively. Other neurochemicals 
were from the RBI, or Sigma. 32p. and 35S-labelled nucleotides a well 
as [12sI]2,5-dimethoxy-4-iodophenyl-2-aminopropane ([125I]DOI)[11] 
(2200 Ci/mmol) were from New England Nuclear. 
2.2. Standard molecular biology techniques 
Classical published procedures were used for library screening, plas- 
mid subcloning, and COS cell transfections [8].An hexamer 32p-labelled 
PstI fragment was used to probe a Northern blot containing human 
RNA samples (Clontech), treated as recommended by the manufac- 
turer, and exposed for 2 weeks. 
2.3. PCR experiments 
We synthesised degenerate oligonucleotides coding for the mouse 
5-HT2B IIIrd and Vllth transmembrane (TM) domains sequences. 
1/tg of human genomic DNA was PCR amplified for 20 cycles with a 
first two sets of primers. 1/10th of the reaction was re-amplified with 
a second set of primers for 20 more cycles. Products were used as probes 
to screen a human lambda GEM genomic library. From the sequence 
we designed oligonucleotides o PCR-screen several human cDNA 
libraries. 
2.4. [~251]DOI binding assays 
[1251]DOI was used as the radioligand to detect expression of the 
5-HT2B gene product in membrane fractions isolated from COS-1 cells 
48 h after DNA transfection. Briefly, cells were resuspended in cold 
4 mM EDTA, 1 mM EGTA, 0.1 mM PMSF, 10 mM imidazole buffer 
pH 7.3 and centrifuged for 10 min at 5,000 × g. The resulting superna- 
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tant was poured onto a 20% sucrose cushion, and centrifuged 90 min 
at 100,000 × g. The pellet containing membranes was resuspended in 75 
mM KCI, 5 mM MgC12, 1 mM EGTA, 10 mM imidazole buffer, pH 
7.3, and used for binding assays. The incubation medium (200/~1) 
contained 50/tl of radioligand (0.1-10 nM of [125i]DOi) ' 50/~1 of buffer 
(50 mM Tris buffer, pH 7.40) alone or containing competing drug, and 
100/zl of membrane suspension (protein concentration, 50/tg/ml). The 
mixture was incubated at 30°C for 30 min. The assay was terminated 
by addition of ice-cold iso-osmotic solution, and rapid filtration 
through GF/B filters, followed by 4 washes of 5 ml of ice-cold buffer. 
Filters were dried rapidly and their radioactivity determined by 
y-radiation counting. Non-specific binding, determined in the presence 
of 10/zM unlabelled DOI, represented about 30% of total binding. 
Competition studies for [~25I]DOI binding were performed byadding 
increasing concentrations of test drug to the reaction. Up to ten differ- 
ent concentrations of each competing drug were used. Each value, 
expressed as pKD (- log mol/l) is the mean of at least 3 independent trial 
runs in triplicate. Data were analysed using the iterative non-linear 
regression fitting program LIGAND (Version 3.0; Mc Pershon 1985) 
and RSI (Release 4.0). 
3. Results 
3.1. Sequence comparison of the human 5-HT2B receptor 
We used G protein-coupled receptor (GPR) homology at the 
amino acid level, especially within the TM regions, to generate 
5-HT2B-specific probes to screen a human liver cDNA library. 
The complete cDNA contains an open reading frame of 1443 
bp encoding a protein of 481 amino acids with a predicted 
molecular weight of 54,258 Da. This deduced protein has exten- 
sive homology with other members of the GPR family. When 
compared with other 5-HT2 receptors, the human sequence 
displays only 79 and 82% identity to the rat and mouse 5-HT2B 
proteins, respectively. By comparison, the homologies between 
the 5-HT2A or the 5-HT2C receptors from different species 
have homologies over 95 and 85%, respectively, and the rat and 
mouse 5-HT2B have 88% homology over the TM domains. 
Alignment of the TM region of 5-HT2 receptors places this 
receptor within the 5-HT2B subfamily [12], being slightly more 
divergent from 5-HT2A than from 5-HT2C; Homologies reach 
71% with the human 5-HT2A receptor and 73% with the human 
5-HT2C [13] and are around 70% for the 5-HT2A and 5-HT2C 
receptors of the same species. In addition, the human 5-HT2B 
genomic structure includes two introns (Fig. 1), which are pres- 
ent at identical positions to the introns in the 5-HT2A gene [14], 
and lack the first intron of the 5-HT2C gene [15]. This confirms 
a probable common evolutionary origin for the 5-HT2 sub- 
class, different from the 5-HT1 family which is devoid of in- 
trons. 
3.2. Pharmacology of the human 5-HT2B receptor 
After introduction of the cDNA coding sequence into the 
eukaryotic vector pSG5 [16] and transfection of the monkey 
kidney COS-1 cells, the pharmacological profile of the 5-HT2B 
receptor was analysed. Steady-state binding assays with 
[125I]DOI demonstrated that this ligand interacts specifically 
with the transfected COS-1 membrane preparation (and not to 
non-transfected cells) with high affinity and in a saturable fash- 
ion. The resulting saturation data exhibits a best-fit o a single 
site mode with an apparent Kd of 11.8 + 1.6 nM and a Bmax of 
4.6 + 1.4 pmol of receptor/mg of protein. The K d values of DOI 
for the mouse 5-HT2B receptor is 25 nM [8]. Competitive inhi- 
bition studies were performed in order to refine the pharmacol- 
ogical profile of this receptor. Inhibition of the [125I]DOI bind- 
ing by various drugs resulted in monophasic curves best fitted 
by a one-site binding model. We observed the following rank 
order of potencies for selected drugs (Table 1): N-acetyl 
5-HT = pizotifen > 5-HT > ritanserin--5-MeOH-tryptamine = 
methiothepine--- 5 CT = yohimbine = mesulergine > cyprohepta- 
dine---RU24 969---methysergide=TFMPP > rauwolscine=2-Me- 
5-HT > setoperone--~-Me-5-HT-tryptamine > ketanserin >> 
8-OH-DPAT. The high affinity of this receptor for serotonin 
would place it in the 5-HT1 family of receptors, despite the low 
affinity for the 5-HT1A-selective agonist 8-OH-DPAT. In addi- 
tion the poor competition by the 5-HT3-selective compounds 
ICS 205-930, MDL 72222, and quipazine rule out the possibil- 
ity that this belongs to the 5-HT3 family. The receptor affinity 
for ketanserin is too low for it to be a typical 5-HT2, although 
the high affinity that it has for the 5-HT2 antagonist pizotifen 
is a discriminative characteristic of this receptor. We noted the 
unexpectedly high affinity of compounds uch as 5-carboxy- 
amido-tryptamine (5-CT), yohimbine, and RU 24969, which 
are typical 5-HT1D receptor ligands. The human 5-HT2B pKD 
values were compared with those of other 5-HT receptors (Fig. 
2). Using the non-parametric Spearman rank correlation test, 
we find that correlation with the mouse 5-HT2B (r = 0.592, 
P < 0.01, n = 35) receptor is significant, although the strongest 
correlation is obtained for the rat 5-HT2B receptor (r = 0.864, 
P < 0.005, n = 7; Fig. 2A,B; Table 2). Moreover a significant 
correlation is observed with the human brain 5-HT 1D receptor 
pharmacology (r = 0.433, P < 0.05, n = 24; Fig. 2C; Table 2), 
as well as with the human saphenous vein pharmacology values 
(r = 0.618, P < 0.05, n = 11; Fig. 2D). 
3.3. Pattern of 5-HT2B expression in human tissues 
In order to have more complete information concerning the 
in vivo expression of this serotonin receptor, Northern blot was 
performed (Fig. 3). A single hybridizing mRNA of about 4.5 
kb was detected in the human liver. Transcripts were also de- 
tectable in lung, heart and kidney mRNA. Fainter signals were 
observed in the brain and placenta (visible on the original 
autoradiography). We extended and confirmed these observa- 
tions by PCR-screening of different human cDNA libraries: the 
identical 5-HT2B cDNA sequence isalso detected in the human 
spinal cord, foetal brain, aorta, internal mammary artery, pla- 
centa, neuroblastoma cell line SHSY-5Y, and CSH carcinoid 
tumour libraries. 
4. Discussion 
4.1. The structure of the human 5-HT2B receptor is distantly 
related to the other 5-HT2B receptors 
The comparison of the human, rat and mouse 5-HT2B recep- 
tor protein sequences shows less homology than that observed 
between either the 5-HT2A or 5-HT2C receptors of different 
species. In addition, conserved DNA sequences outside of the 
5-HT2B coding sequence (not shown) may argue in favour of 
homologous subtypes. These observations are of interest since 
it is still debatable whether the differences observed between 
species represent new subtypes or not [17]. 
As for the other 5-HT2B receptors, consensus sequences for 
phosphorylation by protein kinases are found in the cytoplas- 
mic regions of the human 5-HT2B, in addition to the presence 
of 19 Ser or Thr residues within the 96 carboxy-terminal resi- 
dues (Fig. 1). We observed that, after deletion of the last 
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1 TGCTGACCACTGTTCGGAACGGGATTGAATCACAGAAAAACAGCAA ATG GCT CTC TCT TAC AGA GTG TCT 70 
1 M A L S Y R V S 0 
71 
9 
131 
29 
191 
49 
GAA CTT CAA AGC ACA ATT CCT GAG CAC ATT TTG CAG AGC ACC TTT GTT CAC GTT ATC TCT 
E L Q S T I P E H I L Q S T F V H V I S 
TCT AAC TGG TCT GGA TTA CAG ACA GAA TCA ATA CCA GAG GAA ATG AAA CAG ATT GTT GAG 
S ~N~ W S G L Q T E S I P E E M K Q I V E 
I 
E Q G N K L H 'J W A A L L I L M V I I P T 
P A L T I ~1 A M W P L P L L C 
~':~ I GTG I GATD CGTR TACy ATAI GCCA AITC AAAK ~G CCAp ATCI CAG.Q GCCA ~T CAAQ TAT AACN TCAs 
IV 
169 A T A K T V W L I S I A 
6111 CCA GTC CCT AITT A~ GGG ATA GAG ACT GAT GTG GAC AAC CCA RA; RAN T ATIC ACT TGT GTG 
189 I P V K G I E T D V D P C V 
209 L T K R G D L F G S L A A F T 
V 
273911 CCTp CTTL GCAA AITT ATGM AITT GTC ACCT TACy T 7 CLTC ACTT ATCI CATH GCTA TTAL CAGQ IAAKG AAGK GCTA 
791 TAC TTA GTC AAA AAC AAG CCA CCT CAA CGC CTA ACA TGG TTG ACT GTG TCT ACA GTT TTC 
249 Y L V K N K P P Q R L T W L T V S T V F 
851 CAA AGG GAT GAA ACA CCT TGC TCG TCA CCG GAA RAG GTG GCA ATG CTG GAT GGT TCT CGA 
269 Q R D E T P C S S P E K V A M L D G ~ R 
911 AAG GAC AAG GCT CTG CCC AAC TCA GGT GAT GAA ACA CTT ATG CGA AGA ACA TCC ACA ATT 
289 K D K A L P N S G D E T L M R R T S T I 
309 G K V Q S N Q R A K I V L G I 
VI 
I031 1 ~G329 TTT TTC CTCL TTT TTGL CTT ATGM TGG TGTc CCCp ~F C T 7 ATTI ACAT AANT ATAI ACTT TTAL GTTv 
349 I L C ID  S C N Q T T L Q M L L E I F V W I 
VII 
1211 GA, ocA 7 ,  ooc coA ,A ,  ,o t i s ,  
389 A G R Y T C I N Y 
1271 AGA AAA CGC TCC AGT AAG ATC TAC TTC CGG AAT 
409 R K R S S K I Y F R N 
1331 AAG AAA CAT GGA ATT CGA AAT GGG ATT AAC CCT 
429 K K H G I R N G I N P 
1391 CGA AGT TCA ACC ATT CAG TCT TCA TCA ATC ATT 
449 R S S T I Q S S S I I 
1451 AAT GAA GGT GAC ~ ACT GAA GAG CAA GTT AGT 
469 N E G D K T E E Q V S 
CGG GCC ACA AAG TCA GTA AAA ACT CTC 
R A T K S V K T L 
CCA ATG GCA GAG AAC TCT AAG TTT TTC 
P M A E N S K F F 
GCC ATG TAC CAG AGT CCA ATG AGG CTC 
A M ¥ Q S P M R L 
CTA CTA GAT ACG CTT CTC CTC ACT GAA 
L L D T L L L T E 
TAT GTA TAG CAGAACTGGGAGGTGTCATCAAA 
]L V * 
130 
28 
190 
48 
J 250 
68 
I 310 
88 
J 370 
108 
I 430 
128 
J 490 
148 
550 
168 
I 610 
188 
670 
208 
I 730 
228 
790 
248 
850 
268 
910 
288 
970 
308 
1030 
328 
1090 
348 
1150 
368 
1210 
388 
1270 
408 
1330 
428 
1390 
448 
1450 
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1515 
482 
Fig. 1. Sequence of the human 5-HT2B cDNA. The human 5-HT2B cDNA and deduced protein sequences are displayed. Roman numbers over the 
boxes localise the TM domains. The left numbering is for the DNA sequence on top and for the protein at the bottom. In-frame stop codons are 
shown by *. The circled N indicates putative N-glycosylation sites. Underlined serines or threonines represent consensus for phosphorylation by
protein kinase A and protein kinase C. Intron-exon boundaries are located by vertical and horizontal lines. The thick vertical ine locates the 
C-terminal deletion site. 
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Table 1 
Pharmacology of the human 5-HT2B receptor xpressed in 
as DOI competition 
COS- 1 cells 
pKo S.E.M. 
Agonists 
Antagonists 
1 N-Acetyl-5-HT 8.15 0.15 
2 Tryptamine 6.78 0.11 
3 5-CT 7.46 0.14 
4 (+) ~-Me-5-HT 6.80 0.10 
5 5-HT 7.89 0.14 
6 I-Me-5-HT 5.75 0.12 
7 5-MeOH-tryptamine 7.59 0.14 
8 8-OH-DPAT 5.46 0.09 
9 Quipazine 6.64 0.11 
10 2-Me-5-HT 7.03 0.06 
11 5-Me-tryptamine 4.70 0.11 
12 NNdiMe-5-MeOH-tryptamine 5.17 0.14 
28 RU 24969 7.25 0.11 
13 Ritanserin 7.61 0.08 
14 Pizotifen 8.11 0.06 
15 Methysergide 7.19 0.10 
16 Mesulergine 7.38 0.12 
17 Methiothepine 7.54 0.13 
18 Cyproheptadine 7.26 0.16 
19 Ketanserin 6.42 0.14 
20 Spiperone 4.91 0.15 
21 Setoperone 6.87 0.13 
22 TFMPP 7.16 0.08 
23 Rauwolscine 7.04 0.10 
24 Buspirone 5.79 0.09 
25 Yohimbine 7.41 0.03 
26 Bufotenine 6.25 0.18 
27 ICS 205-930 4.82 0.08 
29 lodocyanopindolol 4.31 0.22 
30 MDL 72 222 <4 0.17 
31 Mianserin 7.14 0.15 
32 Cis-flupenthixol 6.77 0.08 
33 Haloperidol 4.78 0.17 
34 Clozapine 6.33 0.09 
35 Sulpiride 4.30 0.13 
Competition experiment for ['25I]DOI-labeled membrane from tran- 
siently transfected COS-1 cells. Each value, expressed as pKD(-log 
mol/l) is the mean ofat least 3 independent trial runs in triplicate. Ten 
different concentrations of each competing drug were used. 
83 amino acids, the pharmacology was not modified (not 
shown), with a similar Kd for DOI (12.2 + 1.8 vs. 11.8 + 1.6 
nM) although the Bmax is raised (8.7 + 1.7 vs. 4.6 + 1.4 pmol/mg 
of protein). This may indicate that the C-terminal region is 
involved in the receptor desensitisation as demonstrated for the 
fl-adrenergic receptor [18]. 
4.2. The pharmacology of the human 5-HT2B receptor is 
distantly related to the other 5-HT2B receptors 
Confirming the sequence comparisons, the pharmacology of
the human 5-HT2B is different from the pharmacology of other 
species' 5-HT2B receptor. The high affinity for serotonin dis- 
criminates the human 5-HT2B receptor from the mouse (Table 
1). The receptor affinity for serotonin, spiperone, and haloperi- 
dol is close to the typical 5-HT2C values, although the high 
affinity that it has for the compounds yohimbine, RU 24969 
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and rauwolscine gives this human receptor anew original phar- 
macology (Fig. 2). This would relate this receptor to the 
5-HT1B/D subfamily despite its low affinity for the agonist 
sumatriptan (pKo = 4.38). As for the mouse 5-HT2B receptor, 
the LY53857 is non-competitive. Moreover, the pharmacology 
of the rat 5-HT2B receptor [10,19] does not correlate with that 
of the mouse (not shown), but is significantly correlated to that 
of the human 5-HT2B receptor (Fig. 2B). The correlations are 
even stronger if we separate the antagonists from the agonists 
(Table 2): the human 5-HT2B pharmacology correlates with the 
pig 5-HT2C [20] (r = 0.489, P < 0.01, n = 35) or with the antag- 
onist values (r = 0.708, P < 0.01, n = 23) but are not significant 
for the agonist values (Table 2). The correlation with functional 
values of the rat fundus contractions [21] is significant 
(r = 0.723, P < 0.01, n = 14) as well as with those of agonists 
(r = 0.714, P < 0.05, n = 8) which ind ates that the functional- 
ity of the 5-HT2B receptor is conserved. In addition, the re- 
cently reported human 5-HT2B receptor [22] has an identical 
sequence and its IP3 coupling values correlate strongly with our 
binding data (r = 0.964, P < 0.01, n = 7). The correlation with 
the pharmacology of the human 5-HT1D agonists is striking 
since the protein receptor sequence is structurally different, 
despite the possibility that the 5-HT1D receptor interacts with 
the same IP3 effector coupling [23]. 
However, sequence comparison between 5-HT2B and 
5-HT1B/1D receptors reveals few amino acid differences within 
the first TM domains, which may be involved in agonist inter- 
action [24,25]. In particluar, in the second TM domain the 
valine at position 99 in human is present in rat 5-HT2B and in 
all 5-HT1B sequences but is changed to isoleucine in the mouse 
5-HT2B receptor, two amino acids away from the aspartate 
residue which is believed to interact with the amine residue of 
serotonin [24,26]. In the first TM domain, the serine at position 
80 in human and present in the rat sequence, is changed to 
alanine in mouse; as well the leucine at position 62 in the human 
and mouse 5-HT2B sequence is changed to phenylalanine  rat 
5-HT2B. More strikingly, the fifth TM domain has five changes 
between mouse and human 5-HT2B sequence out of which 
three are common to human and rat and may account for some 
of the observed differences inpharmacology. Some pharmacol- 
ogical properties of antagonist compounds relate this receptor 
to the 5-HT1B-1D subfamily. This may correspond to the pres- 
ence of conserved residues in the human 5-HT2B sequence such 
as the isoleucine 234 in TM domain V also found in rat 5-HT2B 
and in all 5-HT1D receptor but not in the mouse 5-HT2B. 
Moreover, the low affinity of the human 5-HT2B for sumatrip- 
tan could be explained by the presence in the VIIth TM domain 
of a valine 366 instead of the threonine known to interact with 
this compound in 5-HT1D receptors [27]. 
4.3. The human 5-HT2B receptor could account for 5-HTIDI5- 
HT2-like activity in the cardiovascular system 
The discrepancy observed between the pharmacology of se- 
rotonin receptors in the cardiovascular system [7] may be, at 
least partially, due to the species divergence, since we have 
__.) 
Fig. 2. Comparison of pharmacological properties of human 5-HT2B and various 5-HT receptors. Comparisons have been performed between values 
for the human 5-HT2B transfected membrane and published values for (A) mouse 5-HT2B [28], (B) rat 5-HT2B [10], (C) human 5-HTIB [32], and 
(D) human saphenous vein [31,33]. Agonist (open symbols), r antagonist (closed symbols) and numbers are as described in Table 1. 
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Table 2 
Spearman correlations between the binding pKD values of the human 5-HT2B and that of various 5-HT receptors (see text for references) 
Agonist + antagonist Agonist Antagonist 
5-HT2B hu/5-HT2B : rat 
5-HT2B hu/5-HT2B : mouse 
5-HT2B hu/5-HT2A: rat 
5-HT2B hu/5-HT2C : pig 
5-HT2B hu/5-HT1D :human 
0.864 (P < 0.005) 0.929 (P < 0.005) 0.774 (P < 0.01) 
(n = 19) (n = 7) (n = 12) 
0.592 (P < 0.01) 0.704 (P < 0.05) 0.667 (P < 0.01) 
(n = 35) (n = 12) (n = 23) 
0.202 (ns) 0.141 (ns) 0.449 (ns) 
(n = 35) (n = 12) (n = 23) 
0.489 (P < 0.01) 0.147 (ns) 0.708 (P < 0.01) 
(n = 35) (n -- 12) (n = 23) 
0.433 (P < 0.05) 0.651 (P < 0.05) 0.381 (ns) 
(n = 24) (n = 8) (n = 16) 
shown that the mouse 5-HT2B receptor is expressed in the 
cardiovascular system [8,28], and we also detected the human 
5-HT2B mRNA in heart, aorta and internal mammary artery 
libraries. Several reports have provided evidence that the pe- 
ripheral action of serotonin cannot be mediated by the known 
5-HT2 receptors. Serotonin coronary vasoconstriction has 
been shown in several species to be mediated by a 5-HT2-1ike 
receptor [29], the effects of which are potentiated in coronary 
artery disease [7]. Serotonin has a direct vasoconstricting effect 
via 5-HT2-1ike receptors when the endothelium is damaged (as 
in coronary artery disease) [30]. More recently, the contractions 
of isolated human coronary artery have been described to be 
under the control of a 5-HT2 receptor and of a '5-HT1D-like' 
receptor [31]. Some of these effects could be mediated by the 
5-HT2B receptor since we found it in heart as well as human 
1 2 3 4 5 6 7 8 
9.S 
7.5 
4.4 
2.4 
1.3 
Fig. 3. Human 5-HT2B in vivo expression visualised by Northern blot 
hybridisation. This Northern blot contains 4/.tg of poly(A) + mRNA 
from different human tissues (Clontech). After hybridisation with a 
random primed labelled cDNA probe, it has been exposed for two 
weeks. Each lane contains the same amount of RNA (not shown). Sizes 
are determined by RNA size marker (Clontech). Lane 1, heart; 2, brain; 
3, placenta; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; 8, pancreas. 
arteries, and since its pharmacology correlates with that of 
human saphenous vein. 
The implications of this work for drug design are profound: 
the same receptor protein in various mammalian species differ 
so greatly in expression sites and in pharmacological properties 
that a particular non-human receptor may be of  very little value 
in the design of human therapeutic agents. 
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